Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 01 Mar 2023
Chirurgiae Master of Neurosurgery, also known as MCh Neurosurgery or MCh of Neurosurgery, is the highest level of training for doctors in India...
Read Full NewsA trial evaluates whether very early FDG PET-guided treatment adaptation after one cycle of brentuximab vedotin-based chemotherapy improves outcomes in Hodgkin lymphoma.
Researchers report that digital monitoring tools may improve symptom tracking, but nurses face added demands linked to alert verification and patient support.
Triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy do not gain a survival benefit from adding atezolizumab to adjuvant capecitabine, shows trial.
Patients treated with datopotamab deruxtecan reported longer preservation of quality of life and physical functioning vs chemotherapy in metastatic TNBC.
The Oncologic Drugs Advisory Committee backed the prostate cancer drug but rejected a novel approach for breast cancer, highlighting challenges in defining clinical meaningfulness.
A phase 3 trial evaluates the efficacy and safety of nilotinib with pegylated interferon alfa-2a in patients with newly diagnosed chronic-phase chronic myeloid leukemia.
Amid a de-escalation trend in breast cancer treatment, less than one third of patients with inflammatory breast cancer receive guideline-endorsed trimodal therapy, despite survival benefits.
1.
Dasatinib Fails to Improve Outcomes in CBF-AML
2.
Rising rates of head and neck cancers in England
3.
Screening for prostate cancer: is it time to give up digital rectal examination?
4.
No Survival Gain With Preoperative CRT Plus Perioperative Chemo for Gastric Cancer
5.
tobacco use, the severity of their symptoms, and their desire to give up smoking among cancer survivors.
1.
Gene Signatures and Their Implications in Oncology: Decoding the Blueprint for Personalized Cancer Treatment
2.
The Statistical Horizon of Colorectal Cancer: From Global Trends to Precision Therapies and Colorectal Cancer 2025 Forecasts
3.
Uncovering the Mystery of the Sessile Serrated Adenoma
4.
Treating Methemoglobinemia: What You Need to Know Now!
5.
Unlocking the Potential of Talquetamab: A Revolutionary Approach to Cancer Treatment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis
2.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VI
4.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge